Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Zengxun Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9278-2462; OpenAlex author ID A5069682885. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 11

  1. Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-025-02561-9↗
  2. Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-024-02938-0↗
  3. Correction: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01721-z↗
  4. BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis. Co-author DOI 10.1038/s41392-023-01478-5↗
  5. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation. Co-author DOI 10.1053/j.gastro.2021.12.249↗
  6. RETRACTED: HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.03.036↗
  7. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.1042/cs20180816↗
  8. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Co-author DOI 10.1158/1078-0432.ccr-18-3533↗
  9. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of … First author DOI 10.1053/j.gastro.2017.09.039↗
  10. Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Co-author DOI 10.1038/ncomms14035↗
  11. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms17060799↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiuchao Wang · 9 shared papers, 2017–2026 · strength 1.17
  2. Tiansuo Zhao · 9 shared papers, 2017–2026 · strength 1.17
  3. Jihui Hao · 9 shared papers, 2017–2026 · strength 1.17
  4. Chongbiao Huang · 9 shared papers, 2016–2026 · strength 1.14
  5. Shengyu Yang · 7 shared papers, 2017–2024 · strength 0.85
  6. Huizhi Sun · 4 shared papers, 2023–2026 · strength 0.74
  7. Song Gao · 5 shared papers, 2018–2024 · strength 0.71
  8. Jing Liu · 4 shared papers, 2022–2024 · strength 0.64
  9. Chao Xu · 3 shared papers, 2023–2026 · strength 0.56
  10. Jie Dong · 3 shared papers, 2016–2022 · strength 0.28
  11. Hui Li · 1 shared paper, 2026 · strength 0.24
  12. He Ren · 2 shared papers, 2018–2019 · strength 0.16
  13. Mingxiao Lang · 2 shared papers, 2016–2019 · strength 0.14
  14. Na Li · 2 shared papers, 2016–2019 · strength 0.14
  15. He Ren · 2 shared papers, 2016–2019 · strength 0.14
  16. Na Li · 2 shared papers, 2017–2018 · strength 0.13
  17. Liangliang Wu · 1 shared paper, 2019 · strength 0.08
  18. Haotian Wang · 1 shared paper, 2019 · strength 0.08
  19. Keping Xie · 1 shared paper, 2019 · strength 0.08
  20. Chao Liu · 1 shared paper, 2019 · strength 0.08
  21. Qi Zhao · 1 shared paper, 2019 · strength 0.08
  22. Jiaqi Shi · 1 shared paper, 2019 · strength 0.08
  23. Lin Fang · 1 shared paper, 2019 · strength 0.08
  24. Changjie Lou · 1 shared paper, 2019 · strength 0.08
  25. Zhiwei Li · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.